Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Hengrui Acquires PI3kδ Inhibitor Rights from Shanghai Lingli Pharma

publication date: Feb 10, 2021

Jiangsu Hengrui Medicine acquired China rights to a PI3kδ inhibitor (YY-20394) from Shanghai Yingli Pharma. Hengrui will make a $20 million investment in Yingli, and it will be responsible for clinical development of the candidate. PI3kδ inhibitors are expected to be effective treatments for hemotological tumors. Founded in 2011, Yingli Pharma is a small-molecule novel drug R&D company focused on treatments for hematological tumors, solid tumors and kidney-related metabolic diseases. It has an R&D center in Zhangjiang Park. More details....

Stock Symbol: (SHA: 600276)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.